Showing 907 results
-
Media Release /Jury verdict in Montgomery County Circuit Court awards $33 million in compensatory damagesJury decides in favor of Novartis and rejects claims for punitive damagesNPC maintains it reported true and…
-
Media Release /- Efficacy and safety profile in large randomized Phase III study consistent with landmark IRIS trial, which established Gleevec as standard of care- Study did not meet primary endpoint at 1 year,…
-
Media Release /-- Exploratory study shows clinical improvement in patients with pulmonary arterial hypertension (PAH) -- Current treatment options have limited benefit for this debilitating, rapidly progressive and…
-
Media Release /- 82% of patients with pancreatic neuroendocrine tumors (NET) experienced clinical benefit when treated with daily RAD001 and monthly Sandostatin LAR Depot- 77% of patients with pancreatic NET…
-
Media Release /-- Regulatory applications to be submitted worldwide for RAD001 first submissions filed in the Hidden List US, EU and Switzerland -- Data showing that RAD001 more than doubles time without tumor…
-
Media Release /Use of Gleevec after surgery shows significant benefit for gastrointestinal stromal tumor (GIST) patients, dramatically reducing risk of relapse GIST, a life-threatening cancer, recurs in as many…
-
Media Release /- RAD001 combined with Herceptin and chemotherapy in two separate Phase I trials halted tumor growth in 77% and 62% of patients, respectively- Novartis to start Phase III clinical trial program to…
-
Media Release /- Partnership aims to provide convenient access to vaccination - helping keep kids and teachers in school and parents at work- "Let's Fight Flu Together!" initiative supports CDC's new vaccination…
-
Media Release /- Tekturna HCT combines the only approved direct renin inhibitor, Tekturna®, with widely used diuretic, hydrochlorothiazide, in a single pill- Data show combination of Tekturna and…
-
Media Release /- Phase III data show rapid and sustained remission in more than 90% of Ilaris-treated patients with cryopyrin-associated periodic syndrome (CAPS) - Ilaris is the first approved treatment for…
